drug · small molecule
nimodipine
Marketedupdated 3mo agoby $GRCE Grace Therapeutics, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for cardiovascular disease and 10 investigational indications.
targets
Mineralocorticoid receptorVoltage-gated L-type calcium channel
all catalysts(0)
nothing on the calendar yet
Trials studying nimodipine
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 16, 2038
~11.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Apr 16, 2038formulationUS 10342787
- Apr 16, 2038formulationUS 10576070
- Apr 16, 2038method-of-use (U-2804)US 11207306
- Apr 16, 2038formulationUS 11413277
- Apr 16, 2038formulationUS 11806338
- Apr 16, 2038formulationUS 12186308
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that